Olympus recently announced its SeleCT Connect program, which uses diagnostic imaging AI to automatically screen which people might benefit from its Spiration valve system.
Spiration is an FDA-designated breakthrough device for treating chronic obstructive pulmonary disease (COPD) patients.
SeleCT Connect — offered as part of Olympus’ SeleCT quantitative computer tomography (QCT) analysis service — is available immediately to more than 9,000 U.S. healthcare through the Nuance AI Marketplace, a workflow-integrated cloud platform for diagnostic imaging AI algorithms.
Read the full story on our sister site Medical Design & Outsourcing.